On March 6, 2023 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases, and its subsidiary Nexcella, Inc. ("Nexcella"), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, reported that Ilya Rachman, M.D., Ph.D., ImmixBio Chief Executive Officer, and Gabriel Morris, Nexcella President, will discuss recent positive NXC-201 clinical data in AL Amyloidosis and Multiple Myeloma in a fireside chat at the 35th Annual Roth Conference on Tuesday, March 14, 2023 at 10:30 a.m. PT (Press release, Immix Biopharma, MAR 6, 2023, View Source [SID1234628191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available at View Source and on the Events & Presentations page located within the Investor Relations section of the ImmixBio website at View Source for at least 30 days following the presentation.

On March 6, 2023 TransCure bioServices reported that it has developed cell line-derived xenograft (CDX) mouse models that will change how researchers tackle the preclinical studies of cancer therapies to treat acute myeloid leukemia (AML) (Press release, TransCure bioServices, MAR 6, 2023, View Source [SID1234628190]). These models enable deeper insights into the efficacy and toxicity of AML therapies, leading to the development of better treatments and bringing hope to the thousands of patients that receive an AML diagnosis each year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AML starts in bone marrow and quickly spreads through the blood, affecting platelets and both red and white blood cells. Preclinical studies typically use standard mouse models to investigate AML therapies, but they are unable to recapitulate human immune responses to the condition (a significant factor that influences the disease) and thereby lack human-relevant efficacy once they reach clinical trials. Due to the fast progression and acute nature of the disease, inadequate mouse models struggle to effectively reflect AML development. Additionally, monitoring of preclinical treatment efficacy is hampered by the cancer cells spreading throughout the body.

The new AML mouse model is generated by injecting mice with AML luciferase tumor cell lines, enabling disease progression monitoring by bioluminescence imaging. Using this model, researchers will be able to more efficiently see how their AML therapies behave in vivo, while gaining an understanding of the functional characterization of AML pathogenesis.

"AML is the most common type of leukemia in adults, yet the challenging nature of the disease means the 5-year survival rate is still under 30 percent," says Dr Sébastien Tabruyn, General Manager and Chief Scientific Officer (CSO), TransCure bioServices. "Our new mouse model represents a significant advance for those trying to develop new AML therapies by providing a greater understanding of what AML looks like, and how treatments affect it. In combination with our other research tools, including flow cytometry and immune profiling, we can support researchers to run more human-relevant preclinical studies and develop truly efficacious therapies for this aggressive cancer."

For further information on TransCure bioServices’ new CDX models for AML, please visit View Source

On March 6, 2023 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology leader, reported that it will participate in the J.P. Morgan 2023 Industrials Conference being held in New York City (Press release, Leidos, MAR 6, 2023, View Source [SID1234628189]).

Roger Krone, Chief Executive Officer, will engage in a question and answer "fireside chat" on March 15, 2023, at 4:40 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source . A replay of the webcast will be available following the presentation at the same link listed above for 30 days afterward.

On March 6, 2023 Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, reported financial results for the fourth quarter and fiscal year 2022 (Press release, Inhibrx, MAR 6, 2023, View Source [SID1234628188]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key Highlights

•INBRX-101: Timing for the potentially registration-enabling trial for Alpha-1 Antitrypsin Deficiency, or AATD, is on track with sites expected to activate and initiate enrollment in April 2023. Initial trial data is anticipated in early 2025. We expect to initiate clinical trial(s) in Graft-versus-host-disease, or GvHD, during the second half of 2023.

•INBRX-105: To date, we have observed a therapeutic window for our targeted 4-1BB agonist in the checkpoint refractory population, with responses both as a single agent and in combination with Keytruda. We expect to announce clinical data from these cohorts during the second half of 2023.

•INBRX-109: We believe we can now more precisely identify the at-risk population for severe liver toxicity in our DR5 agonist trials as elderly individuals with fatty liver disease. Enrollment is paused while we implement the Hepatic Steatosis Index, or HSI, into our screening criteria protocol. We expect enrollment to resume by the middle of the year and do not anticipate this to impact the timeline for completion of the potentially registration-enabling trial in chondrosarcoma during the second half of 2024.

Financial Results
•Cash and Cash Equivalents. As of December 31, 2022, Inhibrx had cash and cash equivalents of $273.9 million, compared to $131.3 million as of December 31, 2021.
•R&D Expense. Research and development expenses were $30.5 million during the fourth quarter of 2022, compared to $18.6 million during the fourth quarter of 2021. Research and development expenses were $110.2 million during the fiscal year 2022, compared to $71.4 million during the fiscal year 2021. Clinical trial expenses increased related to the progression of the Company’s four Phase 1 trials and its potentially registration-enabling Phase 2 trial, which was initiated during the second quarter of 2021. The Company also incurred increased contract manufacturing expenses due to greater production run costs at its contract development and manufacturing organization partners, including drug substance batch manufacturing in preparation for a Phase 2 trial supply and pilot batch production for one of its preclinical candidates. Personnel-related costs also increased during both periods, partially attributable to an increase in headcount as the Company continues to expand its clinical operations and technical operations teams as well as increased salaries and the expansion of our bonus eligibility pool in the current year.
•G&A Expense. General and administrative expenses were $5.3 million during the fourth quarter of 2022, compared to $3.6 million during the fourth quarter of 2021. General and

Exhibit 99.1
administrative expenses were $21.1 million during the fiscal year 2022, compared to $12.4 million during the fiscal year 2021. This overall increase in both periods was primarily driven by an increase in personnel-related costs, in part due to the expansion of the Company’s commercial strategy team as well as an increase in salaries and the expansion of our bonus eligibility pool in the current year. In addition, market research and other scientific publication expenses were incurred related to its continued pre-commercialization efforts for INBRX-101 and INBRX-109. The Company also incurred increased accounting and legal fees as a result of the establishment of its ATM facility and the continued expansion of its intellectual property portfolio.
•Net Loss. Net loss was $40.9 million during the fourth quarter of 2022, or $0.95 per share, compared to $21.2 million during the fourth quarter of 2021, or $0.55 per share. Net loss was $145.2 million during the fiscal year 2022, or $3.62 per share, compared to $81.8 million during the fiscal year 2021, or $2.15 per share.

On March 6, 2023 Corcept Therapeutics Incorporated (Nasdaq: CORT) ("Corcept"), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported that it has commenced a modified Dutch Auction tender offer for the purchase of up to 7,500,000 shares of Corcept’s common stock, par value $0.001 per share (each, a "Share," and collectively, "Shares") or such lesser number of Shares as are properly tendered and not properly withdrawn, at a price not greater than $22.00 per Share nor less than $19.25 per Share, to be paid to the seller in cash less any applicable withholding taxes (Press release, Corcept Therapeutics, MAR 6, 2023, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announces-commencement-tender-offer-0 [SID1234628187]). The tender offer is made in accordance with the terms and subject to the conditions described in the offer to purchase, the related letter of transmittal and other related materials, as each may be amended or supplemented from time to time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The closing price of the Shares on The Nasdaq Stock Market on March 3, 2023, the last full trading day before the start of the tender offer, was $19.20 per Share. The tender offer is scheduled to expire one minute after 11:59 P.M., New York City Time, March 31, 2023, unless the offer is extended or terminated.

Corcept believes that the repurchase of Shares pursuant to the tender offer is consistent with its long-term goal of maximizing stockholder value and that the tender offer is an efficient way to give stockholders the opportunity to receive a return of their investment by tendering some or all of their Shares.

The tender offer is contingent upon at least 3,000,000 Shares being tendered. The tender offer is also subject to terms and conditions, which are described in detail in the offer to purchase. Specific instructions and a complete explanation of the terms and conditions of the tender offer are contained in the offer to purchase, the related letter of transmittal and other related materials, which will be mailed to stockholders of record promptly.

None of Corcept, the members of its Board of Directors, the dealer manager, the information agent or the depositary for the tender offer makes any recommendation as to whether or not any stockholder should participate in the tender offer or as to the purchase price or purchase prices at which stockholders may choose to tender their Shares.

The sole dealer manager for the tender offer is Piper Sandler & Co. D.F. King & Co., Inc. is serving as the information agent for the tender offer and Continental Stock Transfer & Trust Company is serving as the depositary. For all questions relating to the tender offer, please contact the information agent, D.F. King & Co., Inc. at [email protected] or call toll-free at 1 (800) 821-8781, or call the dealer manager, Piper Sandler & Co. at (312) 267-5100.